Studies done in various countries, including South Africa, have shown that lenacapavir is highly effective for HIV prevention.

Ian L. Haddock, founder of the Normal Anomaly Initiative, participated in the trials for lenacapavir, an FDA-approved drug ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men.

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.

Lenacapavir is given in two injections that have to be delivered subcutaneously, something that “takes training and time” to learn, National Institute of Allergy and Infectious Diseases ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

“Lenacapavir represents a major scientific advance — it’s the first long-acting injectable HIV prevention strategy that requires dosing just twice a year,” according to Paul E. Sax, MD ...